Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 639
- Registration Number
- NCT00325676
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Somerset-West, South Africa
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 74
- Registration Number
- NCT00325728
The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Lansoprazole microgranules suspensionDrug: Placebo
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 162
- Registration Number
- NCT00324974
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- Drug: Dexlansoprazole MRDrug: Placebo
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 445
- Registration Number
- NCT00321737
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Dexlansoprazole MRDrug: Placebo
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 947
- Registration Number
- NCT00321984
Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 25
- Registration Number
- NCT00316992
Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
Phase 2
Completed
- Conditions
- AnemiaChronic Kidney DiseaseChronic Renal FailurePure Red Cell Aplasia
- Interventions
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 22
- Registration Number
- NCT00314795
- Locations
- 🇬🇧
Research Facility, London, United Kingdom
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2000
- Registration Number
- NCT00312806
- Locations
- 🇬🇧
Altana Pharma/Nycomed, Trowbridge, United Kingdom
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
Phase 2
Terminated
- Conditions
- Papillomavirus Infections
- Interventions
- Drug: 851B
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 538
- Registration Number
- NCT00312286
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3323
- Registration Number
- NCT00306384
© Copyright 2025. All Rights Reserved by MedPath